View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2017	Aug. 01, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Entity Registrant Name	Protalix BioTherapeutics, Inc.
Entity Central Index Key	0001006281
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	PLX
Entity Common Stock, Shares Outstanding		133,355,039

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 34,533	$ 63,281
Accounts receivable - Trade	3,005	693
Other assets	4,081	2,321
Inventories	7,059	5,245
Assets of discontinued operation	213	327
Total current assets	48,891	71,867
FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT	1,951	1,677
PROPERTY AND EQUIPMENT, NET	8,158	8,703
Total assets	59,000	82,247
Accounts payable and accruals:
Trade	7,852	4,007
Other	9,339	7,496
Convertible notes		53,872
Deferred revenues	1,925	837
Total current liabilities	19,116	66,212
LONG TERM LIABILITIES:
Convertible notes	53,580	19,343
Liability for employee rights upon retirement	2,671	2,348
Promissory note	4,301	4,301
Total long term liabilities	60,552	25,992
Total liabilities	79,668	92,204
COMMITMENTS
CAPITAL DEFICIENCY
Total shareholders’ equity (capital deficiency)	(20,668)	(9,957)
Total liabilities net of capital deficiency	$ 59,000	$ 82,247

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

REVENUES

$ 6,358

$ 1,769

$ 9,247

$ 2,448

COST OF REVENUES

(5,523)

(1,675)

(7,611)

(2,198)

GROSS PROFIT

835

1,636

250

RESEARCH AND DEVELOPMENT EXPENSES

^[1]

(9,304)

(10,013)

(15,271)

(17,347)

Less - grants

478

2,194

1,816

3,503

RESEARCH AND DEVELOPMENT EXPENSES, NET

(8,826)

(7,819)

(13,455)

(13,844)

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

^[1]

(2,814)

(2,206)

(5,351)

(4,201)

OPERATING LOSS

(10,805)

(9,931)

(17,170)

(17,795)

FINANCIAL EXPENSES

(3,045)

(901)

(5,132)

(1,805)

FINANCIAL INCOME

1,665

338

(LOSS) INCOME FROM CHANGE IN FAIR VALUE OF CONVERTIBLE NOTES EMBEDDED DERIVATIVE

14,260

(38,061)

FINANCIAL (EXPENSES) INCOME, NET

11,255

(805)

(41,528)

(1,467)

(LOSS) INCOME FROM CONTINUING OPERATIONS

450

(10,736)

(58,698)

(19,262)

LOSS FROM DISCONTINUED OPERATIONS

(117)

(189)

NET (LOSS) INCOME FOR THE PERIOD

$ 450

$ (10,853)

$ (58,698)

$ (19,451)

NET (LOSS) EARNINGS PER SHARE OF COMMON STOCK - BASIC

(Loss) earnings from continuing operations

$ 0.00

$ (0.11)

$ (0.47)

$ (0.20)

Earnings from discontinued operations

0.00

Net (loss) earnings per share of common stock

0.00

(0.11)

(0.47)

(0.20)

NET (LOSS) EARNINGS PER SHARE OF COMMON STOCK - DILUTED

Loss from continuing operations

(0.06)

(0.11)

(0.47)

(0.20)

Earnings from discontinued operations

0.00

Net loss per share of common stock

$ (0.06)

$ (0.11)

$ (0.47)

$ (0.20)

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING (LOSS) INCOME PER SHARE - BASIC

127,523,706

99,758,511

126,000,782

99,737,348

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING (LOSS) INCOME PER SHARE - DILUTED

192,598,389

99,758,511

126,000,782

99,737,348

[1]	Includes share-based compensation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	$ 55	$ 128	$ 120	$ 366
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	$ 43	$ 99	$ 96	$ 236

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)
$ in Thousands

Total

Common Stock [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Balance at Dec. 31, 2015

$ 10,873

$ 100

$ 194,064

$ (183,291)

Balance (in shares) at Dec. 31, 2015

^[1]

99,800,397

Share-based compensation related to stock options

534

Share-based compensation related to restricted stock award

Share-based compensation related to restricted stock award (in shares)

^[1]

7,843

Net loss from continuing operations

(19,262)

Net loss from discontinued operations

(189)

Balance at Jun. 30, 2016

(7,976)

$ 100

194,666

(202,742)

Balance (in shares) at Jun. 30, 2016

^[1]

99,808,240

Balance at Dec. 31, 2016

(9,957)

$ 124

202,575

(212,656)

Balance (in shares) at Dec. 31, 2016

^[1]

124,134,085

Share-based compensation related to stock options

216

Convertible notes conversions

4,137

$ 5

4,132

Convertible notes conversions (in shares)

^[1]

4,948,821

Net loss from continuing operations

(58,698)

Net loss from discontinued operations

Balance at Jun. 30, 2017

$ (20,668)

$ 129

$ 250,557

$ (271,354)

Balance (in shares) at Jun. 30, 2017

^[1]

129,082,906

[1]	Common Stock, $0.001 par value; Authorized – as of June 30, 2017 - 250,000,000 shares and as of June 30, 2016 - 150,000,000 shares.

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) [Parenthetical] - $ / shares	Jun. 30, 2017	Jun. 30, 2016
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	150,000,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (58,698)	$ (19,451)
Loss from discontinued operations	0	(189)
Loss from continuing operations	(58,698)	(19,262)
Adjustments required to reconcile net loss to net cash used in operating activities:
Share based compensation	216	602
Depreciation	986	1,006
Financial (income) expenses, net (mainly exchange differences)	56	(167)
Changes in accrued liability for employee rights upon retirement	89	107
Gain on amounts funded in respect of employee rights upon retirement	(19)	(3)
Gain on conversion of convertible notes	(739)	0
Change in fair value of convertible notes embedded derivative	38,061	0
Amortization of debt issuance costs and debt discount	1,141	221
Issuance of shares for interest payment in connection with conversions of convertible notes	634	0
Changes in operating assets and liabilities:
(Decrease) increase in deferred revenues (including non-current portion)	1,088	(127)
Increase in accounts receivable and other assets	(3,538)	(4,952)
Increase in inventories	(1,814)	(300)
Increase in accounts payable and accruals (including long term)	5,378	1,273
Net cash used in continuing operations	(17,159)	(21,602)
Net cash provided by discontinued operations	114	285
Net cash used in operating activities	(17,045)	(21,317)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(543)	(575)
Increase in restricted deposit	(343)
Amounts funded in respect of employee rights upon retirement, net	(83)	(84)
Net cash used in investing activities	(969)	(659)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net payment for conversion of convertible notes	(10,961)	0
Net cash used in financing activities	(10,961)	0
EFFECT OF EXCHANGE RATE CHANGES ON CASH	227	228
NET DECREASE IN CASH AND CASH EQUIVALENTS	(28,748)	(21,748)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	63,281	76,374
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD	34,533	54,626
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Purchase of property and equipment	493	656
Convertible notes conversions	3,503
SUPPLEMENTARY DISCLOSURE ON CASH FLOWS
Interest paid	$ 2,330	$ 1,553

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2017

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES

General

Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the “Company”), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the “Subsidiaries”), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company’s proprietary ProCellEx^® protein expression system (“ProCellEx”). To date, the Company has successfully developed taliglucerase alfa (marketed under the name Uplyso^TM in Brazil and certain other Latin American countries and Elelyso^TM in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company’s current strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.

The Company’s product pipeline currently includes, among other candidates:

(1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;

(2) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation; and

(3) OPRX-106, the Company’s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.

Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.

Since its approval by the FDA, taliglucerase alfa has been marketed mainly in the United States by Pfizer as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the “Amended Pfizer Agreement”) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $36.0 million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Pfizer Agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of Elelyso on a 60%/40% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.

On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the “Brazil Agreement”) with Fiocruz, an arm of the Brazilian MoH, for taliglucerase alfa. Fiocruz’s purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the low purchase amounts, the Company is, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil. Approximately 10% of adult Gaucher patients in Brazil are currently treated with Uplyso. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.

In December 2016, the Company received a letter from Fiocruz regarding an order from the Brazilian MoH to purchase alfataliglicerase to treat Gaucher patients in Brazil. The Brazilian MoH’s order consists of a number of shipments during 2017 for a total of approximately $24.3 million. Shipments started in June 2017 and are expected to continue through the end of the year, in increasing volumes.

Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.

Basis of presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2016, filed by the Company with the Commission. The comparative balance sheet at December 31, 2016 has been derived from the audited financial statements at that date.

Net (loss) earnings per share

Basic (loss) earnings per share (“LPS”) are computed by dividing net loss (income) by the weighted average number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), outstanding for each period.

Diluted loss per share is calculated by dividing the net income by the weighted-average number of shares of common stock outstanding during each period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive shares had been issued. Potentially dilutive shares include additional shares issuable upon the assumed conversion of the convertible notes (issued in September 2013 and December 2016).

The loss and weighted average number of shares outstanding used to calculate (loss) earnings per share were as follows:

	Six Months Ended						Three Months Ended
	June 30, 2017			June 30, 2016			June 30, 2017			June 30, 2016
Net loss (income) for the period	$	(58,698	)	$	(19,451	)	$	450		$	(10,853	)
Financial income, net of convertible notes		-			-		$	(11,847	)		-
Loss used for the computation of diluted loss per share	$	(58,698	)	$	(19,451	)	$	(11,397	)	$	(10,853	)
Weighted average shares of common stock outstanding for basic calculation		126,000,782			99,737,348			127,523,706			99,758,511
Weighted average dilutive effect of shares issuable upon conversion of convertible notes		-			-			65,066,683			-
Weighted average dilutive effect of stock options		-			-			8,000			-
Weighted average shares of common stock outstanding for diluted calculation		126,000,782			99,737,348			192,598,389			99,758,511

Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 19,617,149 and 74,087,411 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013 and December 2016) for the six months ended June 30, 2016 and 2017, respectively, and 19,586,488 of Common Stock for the three months ended June 30, 2016 because the effect would be anti-dilutive. The calculation of diluted LPS does not include 5,059,186 shares of Common Stock underlying outstanding options for the three months ended June 30, 2017, because the effect would be anti-dilutive.

INVENTORIES

6 Months Ended

Jun. 30, 2017

INVENTORIES [Abstract]

INVENTORIES

NOTE 2 – INVENTORIES

Inventory at June 30, 2017 and December 31, 2016 consisted of the following:

	June 30,		December 31,
	2017		2016
	(U.S. dollars in thousands)
Raw materials	$	3,130	$	2,591
Work in progress		444		395
Finished goods		3,485		2,259
Total inventory	$	7,059	$	5,245

FAIR VALUE MEASUREMENT

6 Months Ended

Jun. 30, 2017

FAIR VALUE MEASUREMENT [Abstract]

FAIR VALUE MEASUREMENT

NOTE 3 – FAIR VALUE MEASUREMENT

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.

The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.

The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.

The fair value of the convertible notes derivative is based on Level 3 measurement.

As of June 30, 2017, the fair value of the remaining $14.9 million aggregate principal amount of the Company’s outstanding 4.5% convertible promissory notes due 2018, and of the remaining $51.9 million aggregate principal amount of the Company’s outstanding 7.5% secured convertible promissory notes due 2021, is approximately $11.5 million and $ 75.1 million, respectively, based on a Level 3 measurement.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

DISCONTINUED OPERATIONS

6 Months Ended

Jun. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS

NOTE 4 – DISCONTINUED OPERATIONS

The Company accounted for the termination of the Pfizer Agreement and the sale of the license as a discontinued operation, in accordance with ASU No. 2014-08. The following assets and liabilities associated with the Company’s discontinued operations have been segregated and classified as assets and liabilities of discontinued operations, as appropriate, in the consolidated balance sheets as of June 30, 2017 and December 31, 2016, respectively:

	June 30, 2017		December 31, 2016
	(U.S. dollars in thousands)
CURRENT ASSETS:
Accounts receivable - Trade	$	213	$	327
Total current assets of discontinued operations	$	213	$	327

The following summarizes financial information related to the Company’s discontinued operations in the Company’s consolidated statements of operations for the six months ended June 30, 2017 and June 30, 2016:

	Six months ended June 30,
	2017		2016
		(U.S. dollars in thousands)
REVENUES			$	209
COST OF REVENUES				(373)
GROSS PROFIT				(164)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES				(25)
NET (LOSS) FOR THE PERIOD FROM DISCONTINUED OPERATIONS			$	(189)

CONVERTIBLE NOTES

6 Months Ended

Jun. 30, 2017

CONVERTIBLE NOTES [Abstract]

CONVERTIBLE NOTES

NOTE 5 – CONVERTIBLE NOTES

All of the Company’s outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer’s nonconvertible debt borrowing rate. The Company accounts for the 4.5% convertible notes as liability, on an aggregated basis, in their entirety. The conversion feature for the Company’s 7.5% convertible notes is accounted for as a derivative which is bifurcated from the debt host contract and is measured at fair value through the statement of operations. On April 12, 2017, the Company received approval from its stockholders to issue shares of the Company’s Common Stock in excess of 19.9% of the Company’s outstanding shares of Common Stock immediately prior to the closing of the issuance of the Company’s 7.5% convertible notes to settle conversion requests and pay interest on the Company’s issued 7.5% convertible notes. As a result, the Company reclassified the embedded derivative to equity. During the six months ended June 30, 2017 such measurement of the derivative resulted in a non-cash charge to the Company’s statement of operations of $ 38,061 thousand.

The debt discount and debt issuance costs regarding the issuance of the Company’s outstanding 4.5% convertible notes due 2018 are deferred and amortized over the applicable convertible period (5 years).

Issuance costs regarding the issuance of the Company’s 7.5% convertible notes were allocated to the liability, equity component, derivative and shares of Common Stock based on their relative fair values. Issuance costs that were allocated to liability will be amortized using the effective interest rate, other than issuance costs that were allocated to derivative, which were expensed immediately.

During the six months ended June 30, 2017, note holders converted approximately $10.8 million aggregate principal amount of the Company’s 7.5% convertible notes into a total of 4,948,821 shares of Common Stock and cash payments equal to approximately $11 million.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 6 – SUBSEQUENT EVENTS

On July 24, 2017, the Company entered into a note purchase agreement with certain institutional investors relating to the private issuance and sale by the Company of $10 million aggregate principal amount of its 7.5% convertible notes due 2021.

Concurrently with the consummation of the purchase described above, the Company entered into a privately negotiated exchange agreement with certain of its existing note holders holding the Company’s 4.5% convertible note due 2018 to exchange $9 million aggregate principal amount of the Company’s 4.5% convertible notes due 2018 for $8.55 million aggregate principal amount of 4.5% senior convertible notes due 2022.

Interest payments on both the 4.5% senior convertible notes due 2022 and 7.5% convertible notes due 2021 are payable on a semiannual basis, and the initial conversion rate for the both sets of notes is approximately 1,176 shares of Common Stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $0.85 per share of Common Stock, and is subject to adjustment in certain circumstances.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2017

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

General

General

The Company’s product pipeline currently includes, among other candidates:

(1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;

(2) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation; and

Basis of presentation

Basis of presentation

Net (loss) earnings per share

Net (loss) earnings per share

The loss and weighted average number of shares outstanding used to calculate (loss) earnings per share were as follows:

	Six Months Ended						Three Months Ended
	June 30, 2017			June 30, 2016			June 30, 2017			June 30, 2016
Net loss (income) for the period	$	(58,698	)	$	(19,451	)	$	450		$	(10,853	)
Financial income, net of convertible notes		-			-		$	(11,847	)		-
Loss used for the computation of diluted loss per share	$	(58,698	)	$	(19,451	)	$	(11,397	)	$	(10,853	)
Weighted average shares of common stock outstanding for basic calculation		126,000,782			99,737,348			127,523,706			99,758,511
Weighted average dilutive effect of shares issuable upon conversion of convertible notes		-			-			65,066,683			-
Weighted average dilutive effect of stock options		-			-			8,000			-
Weighted average shares of common stock outstanding for diluted calculation		126,000,782			99,737,348			192,598,389			99,758,511

SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2017

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Schedule of Net (loss) earnings per share

The loss and weighted average number of shares outstanding used to calculate (loss) earnings per share were as follows:

	Six Months Ended						Three Months Ended
	June 30, 2017			June 30, 2016			June 30, 2017			June 30, 2016
Net loss (income) for the period	$	(58,698	)	$	(19,451	)	$	450		$	(10,853	)
Financial income, net of convertible notes		-			-		$	(11,847	)		-
Loss used for the computation of diluted loss per share	$	(58,698	)	$	(19,451	)	$	(11,397	)	$	(10,853	)
Weighted average shares of common stock outstanding for basic calculation		126,000,782			99,737,348			127,523,706			99,758,511
Weighted average dilutive effect of shares issuable upon conversion of convertible notes		-			-			65,066,683			-
Weighted average dilutive effect of stock options		-			-			8,000			-
Weighted average shares of common stock outstanding for diluted calculation		126,000,782			99,737,348			192,598,389			99,758,511

INVENTORIES (Tables)

6 Months Ended

Jun. 30, 2017

INVENTORIES [Abstract]

Schedule of Inventory

Inventory at June 30, 2017 and December 31, 2016 consisted of the following:

	June 30,		December 31,
	2017		2016
	(U.S. dollars in thousands)
Raw materials	$	3,130	$	2,591
Work in progress		444		395
Finished goods		3,485		2,259
Total inventory	$	7,059	$	5,245

DISCONTINUED OPERATIONS (Tables)

6 Months Ended

Jun. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

	June 30, 2017		December 31, 2016
	(U.S. dollars in thousands)
CURRENT ASSETS:
Accounts receivable - Trade	$	213	$	327
Total current assets of discontinued operations	$	213	$	327

	Six months ended June 30,
	2017		2016
		(U.S. dollars in thousands)
REVENUES			$	209
COST OF REVENUES				(373)
GROSS PROFIT				(164)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES				(25)
NET (LOSS) FOR THE PERIOD FROM DISCONTINUED OPERATIONS			$	(189)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

SIGNIFICANT ACCOUNTING POLICIES (Net (loss) earnings per share) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net loss (income) for the period	$ 450	$ (10,853)	$ (58,698)	$ (19,451)
Financial income, net of convertible notes	(11,847)	0	0	0
Loss used for the computation of diluted loss per share	$ (11,397)	$ (10,853)	$ (58,698)	$ (19,451)
Weighted average shares of common stock outstanding for basic calculation	127,523,706	99,758,511	126,000,782	99,737,348
Weighted average dilutive effect of shares issuable upon conversion of convertible notes	65,066,683	0	0	0
Weighted average dilutive effect of stock options	8,000	0	0	0
Weighted average shares of common stock outstanding for diluted calculation	192,598,389	99,758,511	126,000,782	99,737,348

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Oct. 31, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2017
Significant Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		5,059,186	19,586,488	74,087,411	19,617,149
Brazil [Member]
Significant Accounting Policies [Line Items]
Percentage of Adult Gaucher Patients Treated with Uplyso				10.00%
Brazil Agreement [Member] \| Scenario, Forecast [Member]
Significant Accounting Policies [Line Items]
Supply Commitment In Year 2017						$ 24.3
Pfizer Agreement [Member]
Significant Accounting Policies [Line Items]
Proceeds From Exchange For Rights To Royalties	$ 36.0
Pfizer Agreement [Member] \| Pfizer Incorporation [Member]
Significant Accounting Policies [Line Items]
Collaborative Arrangement Revenues and Expenses Sharing Percentage	60.00%
Pfizer Agreement [Member] \| Protalix Bio Therapeutics Incorporation [Member]
Significant Accounting Policies [Line Items]
Collaborative Arrangement Revenues and Expenses Sharing Percentage	40.00%
Amended Pfizer Agreement [Member] \| Protalix Bio Therapeutics Incorporation [Member] \| Brazil [Member]
Significant Accounting Policies [Line Items]
Collaborative Arrangement Revenues and Expenses Sharing Percentage	100.00%

INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Raw materials	$ 3,130	$ 2,591
Work in progress	444	395
Finished goods	3,485	2,259
Total inventory	$ 7,059	$ 5,245

FAIR VALUE MEASUREMENT (Narrative) (Details) $ in Millions	Jun. 30, 2017 USD ($)
Four Point Five Percentage Convertible Notes [Member]
Convertible Debt, Fair Value Disclosures	$ 14.9
Seven Point Five Percentage Convertible Notes [Member]
Convertible Debt, Fair Value Disclosures	51.9
Fair Value, Inputs, Level 3 [Member] \| Four Point Five Percentage Convertible Notes [Member]
Convertible Debt, Fair Value Disclosures	11.5
Fair Value, Inputs, Level 3 [Member] \| Seven Point Five Percentage Convertible Notes [Member]
Convertible Debt, Fair Value Disclosures	$ 75.1

DISCONTINUED OPERATIONS (Balance Sheets) (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Accounts receivable - Trade	$ 213	$ 327
Total current assets of discontinued operations	$ 213	$ 327

DISCONTINUED OPERATIONS (Operations) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
REVENUES		$ 209
COST OF REVENUES		(373)
GROSS PROFIT		(164)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		(25)
NET (LOSS) FOR THE PERIOD FROM DISCONTINUED OPERATIONS		$ (189)

CONVERTIBLE NOTES (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Repayments of Convertible Debt		$ 10,961	$ 0
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	$ 14,260	$ (38,061)	$ 0
Seven Point Five Percentage Convertible Notes [Member]
Debt Conversion, Converted Instrument, Shares Issued		4,948,821
Debt Instrument, Interest Rate, Stated Percentage	7.50%	7.50%
Repayments of Convertible Debt		$ 11,000
Debt Conversion, Original Debt, Amount		$ 10,800
Four Point Five Percentage Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Period		5 years

SUBSEQUENT EVENTS (Narrative) (Details) - USD ($)	Jul. 24, 2017	Jun. 30, 2017
Seven Point Five Percentage Convertible Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		7.50%
Subsequent Event [Member] \| Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 1,000
Debt Instrument, Convertible, Conversion Price	$ 0.85
Shares Issuable Upon Conversion	1,176
Subsequent Event [Member] \| Seven Point Five Percentage Convertible Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 10,000,000
Debt Instrument, Interest Rate, Stated Percentage	7.50%
Subsequent Event [Member] \| Four Point Five Percentage Convertible Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 9,000,000
Debt Instrument, Interest Rate, Stated Percentage	4.50%
Subsequent Event [Member] \| Four Point Five Percentage Senior Convertible Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 8,550,000
Debt Instrument, Interest Rate, Stated Percentage	4.50%